Incretin-Based Therapies Do Not Increase Pancreatic Cancer Risk Among Patients With Type 2 Diabetes

January 3, 2018. This meta-analysis of 33 randomized controlled trials of ≥52 weeks’ duration in 79,971 individuals with type 2 diabetes evaluated the risk of pancreatic cancer in patients using incretin-based therapies vs placebo or other antidiabetic drugs. A total of 87 pancreatic cancer events were observed. Analysis showed no increase in pancreatic cancer risk for patients using incretin drugs vs controls (Peto odds ratio [OR] 0.67; 95% confidence interval [CI]: 0.44-1.02) or in an analysis that included only 6 cardiovascular outcome trials (n=55,248; Peto OR: 0.65; 95% CI 0.42-1.01). Indeed, a subgroup analysis of 59,919 patients who received ≥104 weeks of treatment and follow-up found a reduced pancreatic cancer risk among patients using incretin therapies (Peto OR 0.62; 95% CI: 0.41-0.95). For more details, read the study abstract.